Lupin launches Doxercalciferol Injection

19 Dec 2019 Evaluate

Lupin has launched Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, having received an approval from the United States Food and Drug Administration (USFDA) earlier.

The company’s Doxercalciferol Injection, is the therapeutic generic equivalent of Sanofi Genzyme’s Hectorol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials. It is indicated for the treatment of secondary hyperparathyroidism in adult patients with CKD on dialysis. Doxercalciferol Injection (RLD: Hectorol) had an annual sales of approximately $132 million in the U.S. (IQVIA MAT October 2019). 

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×